Vagal Nerve Stimulator (VNS) for Epilepsy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

A vagal nerve stimulator (VNS) is an implantable neurostimulation device used as adjunctive therapy for drug-resistant epilepsy. It consists of a small titanium-encased pulse generator — similar in size and appearance to a cardiac pacemaker — implanted subcutaneously in the left upper chest wall, connected by a coiled silicone lead to helical electrodes that wrap around the left vagus nerve in the neck. The device delivers programmable intermittent electrical impulses to the vagus nerve, which transmits signals via afferent fibres to the brainstem and from there, through ascending projections to the thalamus and cortical networks, modulating abnormal epileptiform synchrony. The exact mechanism of seizure suppression is multifactorial and incompletely elucidated but involves noradrenergic, serotonergic, and GABAergic pathway modulation. VNS does not cure epilepsy but acts as long-term adjunctive therapy alongside antiseizure medications (ASMs), reducing the frequency and severity of seizures in patients for whom further medication changes have failed or are not tolerated. It has been in clinical use since FDA approval in 1997 and CE mark in Europe, with over one hundred thousand devices implanted worldwide. VNS is also licensed for treatment-resistant depression in the United States.

VNS is indicated for adults and children aged four years and above with drug-resistant focal epilepsy who meet specific criteria. Drug resistance is defined by the International League Against Epilepsy (ILAE) as failure of adequate trials of two or more tolerated and appropriately chosen antiseizure medications, either as monotherapy or in combination, to achieve sustained seizure freedom. Patients must not be candidates for resective epilepsy surgery — either because the epileptogenic zone cannot be identified, is multifocal or bilateral, involves eloquent cortex, or the patient has previously undergone resective surgery without sufficient benefit. Comprehensive presurgical evaluation including prolonged video-EEG telemetry, high-resolution MRI, neuropsychological testing, and in some cases invasive EEG monitoring with subdural grids or stereoelectroencephalography (SEEG) precedes any surgical decision. Patients with tuberous sclerosis complex, Lennox-Gastaut syndrome, Dravet syndrome, and other electroclinical syndromes may also benefit from VNS. The VNS is preferred over resective surgery when the epileptogenic zone is not well localised or safely accessible. In treatment-resistant depression, VNS is considered when at least four adequate antidepressant trials including ECT have failed.

VNS implantation is performed under general anaesthesia by a neurosurgeon. Two incisions are made: a horizontal incision approximately four centimetres long in the left neck along a skin crease to expose the left vagus nerve, and an oblique infraclavicular incision approximately five centimetres long in the upper left chest to create a subcutaneous pocket for the generator. The left vagus nerve is identified in the carotid sheath, dissected free from surrounding tissue, and the two helical electrodes are gently wound around it — the cathode and anode contacts separated by a one-centimetre anchor helix. The lead is tunnelled subcutaneously from the neck to the chest pocket using a trocar. The generator is connected to the lead, placed in the chest pocket, and the incisions are closed in layers. Intraoperative impedance testing confirms lead integrity. Surgery takes sixty to ninety minutes. The device is not activated at surgery but is programmed at the first outpatient appointment two to four weeks later by a neurologist or epilepsy specialist nurse using a programming wand. Standard initial settings are output current 0.25 mA, frequency 30 Hz, pulse width 500 microseconds, with a cycle of thirty seconds on and five minutes off, gradually titrated to therapeutic effect over several months. Patients receive a handheld magnet that triggers an extra stimulation burst by swiping over the generator — some patients use this at the onset of a seizure aura to abort or shorten the seizure.

VNS therapy produces a gradual, progressive reduction in seizure frequency that accumulates over months to years of use. Published long-term data and meta-analyses demonstrate that approximately fifty percent of patients achieve a clinically meaningful reduction of fifty percent or more in seizure frequency after one to two years of therapy. Five to ten percent of patients achieve complete seizure freedom, which is rare with further pharmacotherapy alone. Importantly, clinical response continues to improve with time: data from the Vagus Nerve Stimulation Study Group and subsequent registry studies show progressive improvement in the responder rate from thirty-one percent at the end of the first year to fifty percent at five years and sixty percent at ten years. Beyond seizure frequency reduction, VNS produces improvements in mood, alertness, and quality of life independent of seizure control, possibly mediated by noradrenergic and serotonergic effects — making it uniquely beneficial in epilepsy patients who often have comorbid depression and cognitive difficulties. Seizure severity and post-ictal recovery time are also reduced in many patients even when seizure frequency does not decline dramatically. The SenTiva and AspireSR devices offer closed-loop stimulation that automatically delivers an extra burst when accelerometer-detected tonic-clonic-like movements suggest a seizure is occurring, further improving seizure control.

The most common adverse effect of VNS is stimulation-related voice changes — hoarseness, alteration in vocal quality, or throat discomfort — occurring during active stimulation pulses in approximately thirty to forty percent of patients, particularly at higher output currents. This side effect is manageable by reducing current or pulse width and often lessens with time as tolerance develops. Persistent hoarseness between stimulation cycles or causing significant communication difficulties occurs in fewer than ten percent of patients. Cough, pharyngeal paraesthesia, and dyspnoea during stimulation are also stimulation-related and respond to parameter adjustment. Surgical risks include wound infection (two to three percent of implantations, occasionally requiring device explantation), haematoma, and seroma. Rare but serious surgical complications include vagus nerve injury causing permanent hoarseness, Horner syndrome, and bradycardia or asystole — the last occurring most commonly during intraoperative impedance testing, for which atropine and defibrillation capability are available in the operating room. Long-term VNS use has not been associated with cognitive decline. Sleep-disordered breathing, particularly exacerbation of obstructive sleep apnoea, has been reported, and sleep studies are advisable in patients with symptoms. The device is MRI-conditional under specific protocols at 1.5 Tesla. Battery longevity is five to twelve years depending on settings, after which a generator exchange under local anaesthesia is required.

Most patients are discharged the same day or on the morning following surgery after an overnight observation. Neck soreness from the dissection and chest wall discomfort from the pocket incision are managed with regular paracetamol for five to seven days. Sutures or wound closure strips are removed at ten to fourteen days. Patients may shower with waterproof dressings from forty-eight hours postoperatively. Heavy lifting, strenuous exercise, and full neck rotation are avoided for two to three weeks. The device is activated at the first programming appointment two to four weeks after surgery, starting at low stimulation parameters to minimise side effects during adaptation. Programming sessions are scheduled every two to four weeks during titration, gradually increasing output current until the most therapeutic and well-tolerated parameters are established. The vast majority of therapeutic benefit accumulates over the first one to three years, with ongoing incremental improvement thereafter. The patient and carers are trained to use the magnet for emergency stimulation, with the magnet also pausing stimulation when held continuously over the device — useful for reducing stimulation during a meal or important speech. Annual or biennial review in the epilepsy clinic monitors device function, battery status, seizure diary, and medication review. Any change in seizure pattern, voice quality, or general health triggers a device interrogation.